OpenAI Ignites the AI Healthcare Track: Unisound (09678) Value Reassessment Window Arrives

Recently, OpenAI officially launched its healthcare-exclusive products, ChatGPT Health and the OpenAI for Healthcare platform. This significant move has drawn strong attention from global capital markets like a stone cast into the industry's lake. The AI healthcare track has now moved from a 'ready to burst' phase into an 'accelerated running' stage. Domestic leading enterprise Unisound (09678), which has been strategically positioned for years, is now leveraging its technological barriers, commercial achievements, and favorable policy winds to embrace a historic opportunity for value reassessment.

Track Explosion: Dual Drivers of Policy and Market Propel AI Healthcare into New Investment Blue Ocean

The explosive popularity of AI healthcare is not accidental but rather an inevitable result of the convergence of mature technology, policy support, and market demand. OpenAI’s entry into the healthcare sector not only validates the enormous commercial potential of this track but also accelerates the industry's shift from a technical concept towards essential applications.

In terms of data, the growth momentum of the track is fierce. As of 2024, the global AI healthcare market size has reached $26.65 billion and is expected to soar to $505.59 billion by 2033, with an annual compound growth rate as high as 38.8%. The Chinese market, in particular, represents the most promising growth pole globally, with continuous policy support injecting robust momentum. In November 2025, five departments, including the National Health Commission, jointly issued the 'Implementation Opinions on Promoting and Regulating the Application Development of Artificial Intelligence + Healthcare,' setting clear goals to initially build an AI healthcare application system by 2027 and achieve deep integration by 2030, with key support for AI implementation in core scenarios such as primary diagnosis and hospital intelligence. Driven by both policy and market demand, China's AI healthcare market size is projected to reach RMB 315.7 billion by 2033, with a compound annual growth rate of 43.1% from 2023 to 2033, making it one of the most certain investment blue oceans.

"Mountain-Sea" model builds barriers, authoritative certification demonstrates strong capabilities

Among numerous participants in the field, Unisound's first-mover advantage and technical accumulation stand out. As early as 2016, when most AI companies focused on consumer internet, Unisound proactively entered the "smart healthcare" sector, becoming one of the few domestic enterprises deeply engaged in long-term medical AI. In December 2025, the company released its expert large model for the medical field, "Mountain-Sea・Know-Medicine Large Model 5.0", marking a key transition in its medical AI technology system from "assisted response" to "active collaboration".

This model constructs a technical barrier through a dual-core architecture of "medical text large model + medical multimodal large model", with four core advantages addressing clinical pain points: full-stack capability integration covering core needs such as text processing and intelligent agent collaboration, providing "one-stop" diagnostic support; advanced reasoning ability that can simulate clinical thinking, achieving an evolution from "cognitive brain" to "actor"; multimodal technology accurately identifies imaging lesions, completing cross-modal semantic alignment and joint reasoning; relying on massive high-quality medical data training, information extraction accuracy ranks among the best in the industry, and strict control over medical hallucinations through advanced training paradigms ensures medical safety.

Technical strength has received authoritative certification. In the December 2025 evaluation by the Shanghai Artificial Intelligence Research Institute MedBench 4.0, the "Mountain-Sea・Know-Medicine Large Model 5.0" won three first places in medical intelligence, medical large language models, and medical multimodal large models, surpassing top international models to become the only "triple champion" in the industry, fully verifying its technological leadership.

Commercial breakthrough: 400 hospitals vote with real money, Unisound’s value awakening is underway

Unlike many companies still at the technical concept stage, Unisound has achieved efficient conversion from technology to commercialization, building a complete closed loop of "technology - product - revenue". Currently, the smart healthcare product matrix has formed a nationwide deployment pattern, with solutions implemented in nearly 400 hospitals, and another 700+ entering the testing phase, covering hundreds of top-tier tertiary hospitals, continuously increasing user base and market penetration.

In specific application scenarios, product value is fully demonstrated: the outpatient medical record generation system at Friendship Hospital has a direct citation rate of nearly 90% per medical record, significantly reducing the burden of medical documentation; the DRG/DIP medical insurance payment management system assists large insurance institutions in deploying a national claims risk control platform, improving the efficiency of medical insurance fund usage and risk control capabilities, creating significant clinical and operational benefits.

Large-scale implementation translates into strong revenue growth. In 2024, Unisound's total revenue increased by 29.1% year-on-year, with medical business revenue growing by 34.4% year-on-year, becoming the core growth engine. The Guotai Haitong research report points out that Unisound, as a pioneer in China’s AGI technology industrialization, has not been fully valued for its technical barriers and commercialization capabilities. For the first time, it was given a "buy" rating and a target price of HKD 451.33, expecting revenue to maintain over 35% high-speed growth from 2025 to 2027.

Value reevaluation: Scarce leader encounters opportunities, long-term potential awaits release

Currently, the AI healthcare track is on the eve of concentrated policy dividend release and large-scale commercialization breakout. OpenAI’s entry opens up industry imagination, while policy support provides solid assurance. For investors, the real opportunity lies in identifying companies that can solve clinical pain points and achieve large-scale implementation.

Unisound, with its early-mover advantage in technology barriers, authoritative product certifications, nationwide customer base, and consistently growing revenue, holds a rare leading position in a high-certainty sector. However, the current valuation has yet to fully reflect its true value and growth potential. As the 'Mountain-Sea・Zhiyi Large Model 5.0' undergoes iterative upgrades, expands into new application scenarios, and benefits from favorable policies, Unisound’s commercialization process will accelerate significantly.

At this critical juncture of large-scale AI healthcare adoption, this 'hidden champion' that has deeply cultivated the industry for many years is now facing a historic window for systematic revaluation. Its currently undervalued long-term potential is likely to continue shining amid the explosive growth of the sector, making it an excellent investment target for those seeking exposure to the AI healthcare space.

528K Views